RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
TEL AVIV, Israel and RALEIGH, NC, June 21, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.
TEL AVIV, Israel and RALEIGH, NC, Feb. 23, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
51job, Inc. Enters into a Definitive Agreement for Going-Private Transaction
SHANGHAI, June 21, 2021 /PRNewswire/ -- 51job, Inc. (Nasdaq: JOBS) ("51job", or the "Company"), a l...
RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals
TEL AVIV, Israel and RALEIGH, N.C., Jan. 28, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
ASCO 2022 | Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development
SUZHOU, China, and ROCKVILLE, Md., May 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...
Blackbaud Announces First Featured Speakers and 100 Session Topics for bbcon 2020 Virtual
Dr. Cornel West, Justin Dillon, Meico Marquette Whitlock and Alice L. Ferris to take to the virtual...
LTI Crosses USD 2 billion Annual Revenue Run Rate
- LTI constant currency revenues grow 8.9% QoQ and 25.5% YoY; Net profit up by 20.8% YoY MUMBAI, I...
EHA 2022 | Ascentage Pharma Releases Encouraging Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
SUZHOU, China, and ROCKVILLE, MD, June 12, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...
FOSUN FOR GOOD, CREATING IMPACT: Fosun International Issued its 2023 ESG Report and the Second Climate Information Disclosures Report
HONG KONG, April 26, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fos...
Institute for Real Growth Announces 'IRG 100' Selected Participants for IRG CMO Leadership Program
NEW YORK, Feb. 19, 2020 /PRNewswire/ -- The Institute for Real Growth (IRG) today announced the 'IR...
BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Not intended for US-, Canada- and UK-based media DARMSTADT, Germany and NEW YORK, Dec. 11, 2020 /P...
Companies Must Step Up as Youth Seek Out "Green" Jobs: Accenture
Accenture Research study indicates that 77% of Asia Pacific youth aspire to work in the green econo...
Accenture to Acquire Romp to Boost Brand Transformation Capabilities and Advance Customer Experience Across Southeast Asia
Jakarta-based brand and experience agency will enhance Accenture Song's creativity and brand thinki...
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enr...
Squirrel AI Learning Attends the Web Summit to Talk About the Application and Breakthrough of Artificial Intelligence in the Field of Education
LISBON, Portugal, Dec. 17, 2019 /PRNewswire/ -- Web Summit, a global internet-based summit dubbed b...
Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib
Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe ...
Jelenew creates the first cycling pants that are truly made for women in the world
Disruptive innovation will bring revolutionary changes to the traditional women's cycling apparel i...
2021 .ORG Impact Awards Finalists Named
35 innovative and inspiring mission-driven organizations and leaders selected out of a record 633 ...
CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application
* Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to successfully impro...